

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

7590

9/09/2002

VIKKI MERIWETHER PARALEGAL ARNOLD WHITE & DURKEE P O BOX 4433 HOUSTON, TX 77210-4433

_	EXA	AMINER
	BELYAVSK	(YI, MICHAIL A
	ART UNIT	CLASS-SUBCLASS
	1644	435-816000

DATE MAILED: 09/09/2002

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/464.099	12/16/1999	GERARD FRANCIS BARRY	MOBT:175-2	7129

TITLE OF INVENTION: ANTIBODY IMMUNOREACTIVE WITH A 5-ENOLPYRUVYLSHIKIMATE-3-PHOSPHATE SYNTHASE

1	APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE	
•	nonprovisional	NO	\$1280	\$300	\$1580	12/09/2002	

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED.</u> THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

If the SMALL ENTITY is shown as NO:

- A. Pay TOTAL FEE(S) DUE shown above, or
- B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.
- ☐ Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

	Application No.	Applicant(s)					
	09/464,099	BARRY ET AL.					
Notice of Allowability	Examiner	Art Unit					
	Michael A Dahamahad	4044					
	Michail A Belyavskyi	1644	<u> </u>				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.							
1. This communication is responsive to <u>20 June 2002</u> .							
2. The allowed claim(s) is/are 102-104 and 107.	_						
3. The drawings filed on are accepted by the Examine4. Acknowledgment is made of a claim for foreign priority und							
a) All b) Some* c) None of the:	er 33 0.0.0. § 113(a)-(a) or (i).						
1. Certified copies of the priority documents have	been received.						
2. Certified copies of the priority documents have	been received in Application No	·					
Copies of the certified copies of the priority do	cuments have been received in this	national stage applica	ition from the				
International Bureau (PCT Rule 17.2(a)).							
* Certified copies not received:							
5. Acknowledgment is made of a claim for domestic priority ur		sional application).					
(a) The translation of the foreign language provisional a							
6. Acknowledgment is made of a claim for domestic priority ur	ider 35 U.S.C. 99 120 and/or 121.						
Applicant has THREE MONTHS FROM THE "MAILING DATE" of below. Failure to timely comply will result in ABANDONMENT of t							
7. A SUBSTITUTE OATH OR DECLARATION must be subminformal patent application (PTO-152) which gives reason			NOTICE OF				
1) ⊠ hereto or 2) □ to Paper No (b) □ including changes required by the proposed drawing of the proposed drawing	(a) 🗵 including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached						
Identifying indicia such as the application number (see 37 CFR 1. of each sheet. The drawings should be filed as a separate paper	84(c)) should be written on the draw with a transmittal letter addressed to	ings in the top margin (r the Official Draftsperso	not the back) on.				
9. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT FOR THE	SIT OF BIOLOGICAL MATERIAL HE DEPOSIT OF BIOLOGICAL MA	must be submitted. N ATERIAL.	Note the				
Attachment(s)							
 1 ☐ Notice of References Cited (PTO-892) 3 ☑ Notice of Draftperson's Patent Drawing Review (PTO-948) 5 ☐ Information Disclosure Statements (PTO-1449), Paper No 7 ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 	4⊠ Interview Summ 6⊠ Examiner's Ame	al Patent Application (lary (PTO-413), Paper endment/Comment ement of Reasons for a	No				



PART B - FEE(S) TRANSMITTAL



Complete and send this form, together with applicable fee(s), to: Mail Box ISSUE FEE

HOUSTON, TX 77210-4433

Commissioner for Patents Washington, D.C. 20231

(703)746-4000 <u>Fax</u>

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee swift featings.

maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1) Note: A certificate of mailing can only be used for domestic mailings of the Fec(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. 7590 09/09/2002 VIKKI MERIWETHER PARALEGAL ARNOLD WHITE & DURKEE Certificate of Mailing or Transmission I hereby certify that this Fec(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Box Issue Fee address above, or being facsimile P O BOX 4433

(Depositor's name	transmitted to the USPTO, on the date indicated below
(Signatur	
(Dat	

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/464,099	12/16/1999	GERARD FRANCIS BARRY	MOBT:175-2	7129

TITLE OF INVENTION: ANTIBODY IMMUNOREACTIVE WITH A 5-ENOLPYRUVYLSHIKIMATE-3-PHOSPHATE SYNTHASE

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1280	\$300	\$1580	12/09/2002
EXAMIN	NER	ART UNIT	CLASS-SUBCLASS		
BELYAVSKYI,	MICHAIL A	1644	435-816000		
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.		2. For printing on the patent free the names of up to 3 registered or agents OR, alternatively, (2' single firm (having as a mem attorney or agent) and the nar registered patent attorneys or ag is listed, no name will be printed	patent attorneys) the name of a aber a registered mes of up to 2 gents. If no name		

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignce is identified below, no assignce data will appear on the patent. Inclusion of assignce data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (B) RESIDENCE: (CITY and STATE OR COUNTRY) (A) NAME OF ASSIGNEE

Please check the appropriate assignee category or categories (will not b	e printed on the patent)	☐ individual	☐ corporation or other private group entity	☐ government			
4a. The following fee(s) are enclosed:	4b. Payment of Fee(s):						
□ Issue Fec	☐ A check in the amount of the fee(s) is enclosed.						
□ Publication Fee	☐ Payment by credit card. F						
☐ Advance Order - # of Copies	The Commissioner is here Deposit Account Number	eby authorized t	by charge the required fec(s), or credit any or(enclose an extra copy of this form).	verpayment, to			
Commissioner for Patents is requested to apply the Issue Fee and Publi	cation Fee (if any) or to re-ap	ply any previou	ısly paid issue fee to the application identific	d above.			
(Authorized Signature) (Date)							
NOTE; The Issue Fee and Publication Fee (if required) will not be other than the applicant; a registered attorney or agent; or the assinterest as shown by the records of the United States Patent and Trade	signee or other party in emark Office.						
This collection of information is required by 37 CFR 1.311. The in obtain or retain a benefit by the public which is to file (and by the application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFI estimated to take 12 minutes to complete, including gathering, prepa completed application form to the USPTO. Time will vary depend case. Any comments on the amount of time you require to con suggestions for reducing this burden, should be sent to the Chief Ir Patent and Trademark Office, U.S. Department of Commerce, Wash NOT SEND FEES OR COMPLETED FORMS TO THIS A Commissioner for Patents, Washington, DC 20231.	formation Officer, U.S.						
Under the Paperwork Reduction Act of 1995, no persons are recollection of information unless it displays a valid OMB control numbers.	quired to respond to a						



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/464,099	12/16/1999	GERARD FRANCIS BARRY	MOBT:175-2	7129
75	90 09/09/2002		EXAMIN	ER
VIKKI MERIWE	THER PARALEGAL	BELYAVSKYI, I	MICHAIL A	
ARNOLD WHITE P O BOX 4433	& DURKEE		ART UNIT	PAPER NUMBER
HOUSTON, TX 77	210-4433		1644	
			DATE MAILED: 09/09/2002	

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The patent term adjustment to date is 0 days. If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the term adjustment will be 0 days.

If a continued prosecution application (CPA) was filed in the above-identified application, the filing date that determines patent term adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system. (http://pair.uspto.gov)



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: CCMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/464,099	12/16/1999	GERARD FRANCIS BARRY	MOBT:175-2 71		
7	590 ()9/()9/2002		EXAMINER		
VIKKI MERIWE	ETHER PARALEGAL	_	BELYAVSKYI, I	MICHAIL A	
ARNOLD WHITE P O BOX 4433	& DURKEE	·	ART UNIT	PAPER NUMBER	
HOUSTON, TX 7		_	1644		
UNITED STATES		D	ATE MAILED: 09/09/2002		

Notice of Possible Fee Increase on October 1, 2002

If a reply to a "Notice of Allowance and Fee(s) Due" is filed in the Office on or after October 1, 2002, then the amount due may be higher than that set forth in the "Notice of Allowance and Fee(s) Due" since there may be an increase in fees effective on October 1, 2002. See Revision of Patent and Trademark Fees for Fiscal Year 2003: Notice of Proposed Rulemaking, 67 Fed. Reg. 30634, 30636 (May 7, 2002). Although a change to the amount of the publication fee is not currently proposed for October 2002, if the issue fee or publication fee is to be paid on or after October 1, 2002, applicant should check the USPTO web site for the current fees before submitting the payment. The USPTO Internet address for the fee schedule is: http://www.uspto.gov/main/howtofees.htm.

If the issue fee paid is the amount shown on the "Notice of Allowance and Fee(s) Due," but not the correct amount in view of any fee increase, a "Notice to Pay Balance of Issue Fee" will be mailed to applicant. In order to avoid processing delays associated with mailing of a "Notice to Pay Balance of Issue Fee," if the response to the Notice of Allowance and Fee(s) due form is to be filed on or after October 1, 2002 (or mailed with a certificate of mailing on or after October 1, 2002), the issue fee paid should be the fee that is required at the time the fee is paid. If the issue fee was previously paid, and the response to the "Notice of Allowance and Fee(s) Due" includes a request to apply a previously-paid issue fee to the issue fee now due, then the difference between the issue fee amount at the time the response is filed and the previously paid issue fee should be paid. See Manual of Patent Examining Procedure, Section 1308.01 (Eighth Edition, August 2001).

Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

#24/H

Application/Control Number: 09/464,099

Art Unit: 1644

Page 2

DETAILED ACTION

1. Applicant's election without traverse of Group I, claims 102-104 and 107 in Paper No. 22 is acknowledged.

2. Claims 108 - 111 are withdrawn from further consideration by the Examiner, 37 C.F.R. § 1.142(b) as being drawn to a nonelected invention.

EXAMINER'S AMENDMENT

- 3. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the Issue Fee.
- 4. Authorization for this Examiner's Amendment was given in a telephone interview with Janelle D. Waack on 09/03/02.

IN THE SPECIFICATION:

- 4. On pages 9 –12 in "Brief description of the drawings":
- A) "17 Figures 1A+1B show" has been changed to -- Figures 1A 1B show ---
- B) "12 Figures 3A, 3A,3C, 3D, 3E show" has been changed to -- Figures 3A 3E show ---
- C) "Figure 4A-4E show" has been changed to -- Figures 4A-4E show--.
- D) "1 Figures 5A-5E show" has been changed to -- Figures 5A-5E show--:
- E) "4 Figures 6A + 6B show" has been changed to -- Figures 6A 6B show--
- F) "6 Figures 7A +7 B show" has been changed to -- Figures 7A -7B show -- .-
- G) "8 Figures 8A +8 B show" has been changed to -- Figures 8A -8B show --:
- H) "15 Figures 10A +10 B show" has been changed to -- Figures 10A -10B show -
- I) "Figures 12A +12 B show" has been changed to --Figures 12A -12B show ---
- J) "8 Figures 18A -18 D show" has been changed to --Figures 18A -18D show --.
- K) "12 Figures 19A -19 D show" has been changed to -- Figures 19A -19D show --.
- L) "15 Figures 20A 20 K show" has been changed to -- Figures 20A 20K show --.
- M) "- Figures 21A -21 E show" has been changed to -- Figures 21A -21 E show --.
- N) "- Figures 22A -22 E show" has been changed to -- Figures 22A -22 E show --.
- O) "- Figures 23A -23 D show" has been changed to -- Figures 23A 23 D show --.

IN THE TITLE:

- 5. "Glyphossate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases" has been changed to
- An antibody immunoreactive with a 5-enolpyruvylshikimate-3-phosphate synthase --

Application/Control Number: 09/464,099

Art Unit: 1644

IN THE Claims:

6. Non-elected Claims 108-111 have been canceled.

REASONS FOR ALLOWANCE

1. The following is an Examiner's Statement of Reasons for Allowance:

Claims 102-104 and 107 are pending and allowed.

The prior art does not teach or suggest an antibody immunoreactive with a 5-enolpyruvylshikimate-3-phosphate synthase enzyme, wherein enzyme comprises SEQ ID:3 or SEQ ID NO:70.

2. Formal drawings have been submitted which fail to comply with 37 CFR 1.84. Please see the enclosed form PTO-948.

INFORMATION ON HOW TO EFFECT DRAWING CHANGES

A. Correction of Informalities -- 37 CFR 1.85

New corrected drawings must be filed with the changes incorporated therein. Identifying indicia, if provided, should include the title of the invention, inventor's name, and application number, or docket number (if any) if an application number has not been assigned to the application. If this information is provided, it must be placed on the front of each sheet and centered within the top margin. If corrected drawings are required in a Notice of Allowability (PTOL-37), the new drawings **MUST** be filed within the **THREE MONTH** shortened statutory period set for reply in the "Notice of Allowability." Extensions of time may NOT be obtained under the provisions of 37 CFR 1.136 for filing the corrected drawings after the mailing of a Notice of Allowability. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.

B. Corrections other than Informalities Noted by Draftsperson on form PTO-948.

All changes to the drawings, other than informalities noted by the Draftsperson, MUST be made in the same manner as above except that, normally, a highlighted (preferably red ink) sketch of the changes to be incorporated into the new drawings MUST be approved by the examiner before the application will be allowed. No changes will be permitted to be made, other than correction of informalities, unless the examiner has approved the proposed changes.

Application/Control Number: 09/464,099

Art Unit: 1644

Timing of Corrections

Applicant is required to submit acceptable corrected drawings within the time period set in the Office action. See 37 CFR 1.185(a). Failure to take corrective action within the set (or extended) period will result in ABANDONMENT of the application.

- 3. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
- 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is (703) 308-4232. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Michail Belyavskyi, Ph.D. Patent Examiner Technology Center 1600 September 3, 2002

CHRISTINA CHAN
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

	Application No.	Applicant(s)	
Interview Summary	09/464,099	BARRY ET AL.	
interview dammary	Examiner	Art Unit	
	Michail A Belyavskyi	1644	
All participants (applicant, applicant's representative, PTO	personnel):		
(1) <u>Michail A Belyavskyi</u> .	(3)		
(2) Janelle Waack.	(4)		
Date of Interview: 03 September 2002.			
Type: a)⊠ Telephonic b)□ Video Conference c)□ Personal [copy given to: 1)□ applicant 2	²)☐ applicant's representative	∍]	
Exhibit shown or demonstration conducted: d) Yes If Yes, brief description:	e)⊠ No.		
Claim(s) discussed: <u>102-104,107,108-111</u> .			
Identification of prior art discussed: none.			
Agreement with respect to the claims f)⊠ was reached.	g) was not reached. h)] N/A.	
Substance of Interview including description of the general reached, or any other comments: \underline{mn} .	nature of what was agreed to	if an agreement	was
(A fuller description, if necessary, and a copy of the amendallowable, if available, must be attached. Also, where no coallowable is available, a summary thereof must be attached	opy of the amendments that w		
 i) ☐ It is not necessary for applicant to provide a se checked). 	parate record of the substance	e of the interview	(if box is
Unless the paragraph above has been checked, THE FORMUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. action has already been filed, APPLICANT IS GIVEN ONE STATEMENT OF THE SUBSTANCE OF THE INTERVIEW reverse side or on attached sheet.	(See MPEP Section 713.04) MONTH FROM THIS INTERV	. If a reply to the (IEW DATE TO F	last Office

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required